0000899243-19-029172.txt : 20191213
0000899243-19-029172.hdr.sgml : 20191213
20191213174642
ACCESSION NUMBER: 0000899243-19-029172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191211
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pizzo Philip A.
CENTRAL INDEX KEY: 0001574286
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 191285454
MAIL ADDRESS:
STREET 1: ONE COMMERCE STREET
STREET 2: SUITE 2550
CITY: MEMPHIS
STATE: TN
ZIP: 38103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-11
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001574286
Pizzo Philip A.
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2019-12-11
4
M
0
15000
18.85
A
15000
D
Common Stock
2019-12-11
4
M
0
15000
28.45
A
30000
D
Common Stock
2019-12-11
4
S
0
27868
76.5225
D
2132
D
Common Stock
2019-12-11
4
S
0
2132
77.2507
D
0
D
Stock Option (Right to Buy)
18.85
2019-12-11
4
M
0
15000
0.00
D
2026-06-15
Common Stock
15000
0
D
Stock Option (Right to Buy)
28.45
2019-12-11
4
M
0
15000
0.00
D
2027-06-19
Common Stock
15000
0
D
Represents the weighted average sale price of the shares sold from $76.12 to $77.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2.
Represents the weighted average sale price of the shares sold from $77.12 to $77.38 per share.
The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 16, 2016.
The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 20, 2017.
/s/Lesley Ann Calhoun, as Attorney-in-Fact
2019-12-13